New eczema drug 611 shows promise in large chinese trial
NCT ID NCT06173284
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested a new drug called 611 in 519 Chinese adults with moderate-to-severe atopic dermatitis (eczema). 611 is an antibody that blocks a key driver of allergic inflammation. The study compared 611 injections to a placebo over 16 weeks, measuring skin clearance and severity scores. The trial is completed, and results will show if 611 can effectively reduce eczema symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 611 (a lab-made antibody that blocks a protein involved in allergic inflammation)
- What this could lead to
- If successful, 611 could offer a new treatment option for Chinese adults with moderate-to-severe eczema, helping to clear skin and reduce itch.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. As a biologic, it may have side effects like injection reactions or infections. It may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Dermatology Hospital of Jiangxi Province
Nanchang, Jiangxi, 330200, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
The Fourth Affiliated Hospital Zhejiang University School of Medicine
Jinhua, Zhejiang, 322000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- New eczema drug enters first human tests
- Eczema drug study pulled before it started